InVivo submitted the changes in late November, according to a report. InVivo plans to devote increased resources to the trial, diverting from its hydrogel drug delivery platform to focus on the scaffold, which seeks to treat acute spinal injuries.
The company will distribute the protocols and supporting material to the 6 remaining clinical trial sites before finalizing contracts. InVivo hopes to begin trials in early March, according to a press release.
The news of the trial caused another jump in the company’s stock. NVIV stock jumped 11.6% after the news was reported late on Dec. 26. InVivo stock closed last night at $2.24, a 2.3% loss on the day.